Business Context and Reporting Period
InterCure Ltd., a foreign private issuer based in Herzliya, Israel, filed Form 6-K on October 8, 2025. The filing reports financial results for the six months ended June 30, 2025 (First Half 2025).
Key Financial Metrics
- Revenue: NIS 130 million for the six months ended June 30, 2025.
- Cash Flow: The company reported positive operating cash flow for the period.
- Profit, Margins, Debt, and Liquidity: The provided filing text does not provide clear values for net profit, specific margin percentages, total debt, or detailed liquidity ratios.
Material Changes
The filing text does not provide specific comparative figures for the prior period (First Half 2024) to quantify material changes in revenue or profitability.
Guidance, Outlook, and Risks
The filing text does not contain specific forward-looking guidance, management commentary on future outlook, or a detailed list of risks and contingencies beyond the standard inclusion of the MD&A document as an exhibit.
Investor Verification Checklist
- Verify the exact amount of positive operating cash flow reported in Exhibit 99.2.
- Review the Condensed Consolidated Unaudited Interim Financial Statements (Exhibit 99.2) for net income/loss and specific margin calculations.
- Examine the Management's Discussion and Analysis (Exhibit 99.3) for year-over-year growth rates and specific risk factors.
- Confirm the company's current debt obligations and liquidity position as of June 30, 2025.